Candesartan + Placebo

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Glucose Intolerance

Conditions

Glucose Intolerance, Obesity

Trial Timeline

Jun 1, 2006 → Feb 1, 2012

NCT ID

NCT00319202

About Candesartan + Placebo

Candesartan + Placebo is a approved stage product being developed by AstraZeneca for Glucose Intolerance. The current trial status is terminated. This product is registered under clinical trial identifier NCT00319202. Target conditions include Glucose Intolerance, Obesity.

What happened to similar drugs?

3 of 5 similar drugs in Glucose Intolerance were approved

Approved (3) Terminated (2) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

❌UX007 + PlaceboUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00699452	Phase 3	UNKNOWN	May 1, 2009	Dec 1, 2014	Aortic Valve Stenosis
NCT00319202	Approved	Terminated	Jun 1, 2006	Feb 1, 2012	Glucose Intolerance
NCT00328302	Approved	UNKNOWN	Sep 1, 2000	Apr 1, 2006	Diabetes, Type I
NCT00634712	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634309	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634400	Phase 3	Completed	Mar 1, 1999	May 1, 2003	Congestive Heart Failure

Competing Products

17 competing products in Glucose Intolerance

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
AZD1656	AstraZeneca	Phase 1	29
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg	Merck	Phase 2	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007	Ultragenyx Pharmaceutical	Phase 2	21
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 3	26
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	25
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25